Logo
Login
$ADGM
$0.10 -$0.01 (5.75%) Close

Company Executives

$ADGM Management Team

Mr. Joseph Edelman

Independent Chairman of the Board

Age 67
Compensation -
Sex Male

Mr. Adam Stone

Chief Executive Officer

Director

Age 44
Compensation -
Sex Male

Mr. Michael Altman

Chief Financial Officer

Director

Age 41
Compensation -
Sex Male

Mr. Konstantin Poukalov

Chief Business Officer

Age 39
Compensation -
Sex Male

Mr. Patrick Morrow

Investor Relations

Age -
Compensation -
Sex Male

Board of Directors

From the proxy statement filed Apr 30, 2026
Directors
7
serving now
Independent
6 of 7
stated in the proxy
Average tenure
1.9 years
from year joined
CEO also chairs the board
No
Orly Mishan
Director Age On board Independent Committees Other public boards 2025 pay Source
Orly Mishan
Board chair
 53 2024
2 years
 Independent
Compensation
None stated $253,534
Sean Salmon
61 2025
1 year
 Independent
Audit
None stated $66,484
Sandra Gardiner
60 2024
2 years
 Independent
Audit · Chair
None stated $120,460
Keyvan Mirsaeedi-Farahani
39 2024
2 years
 Independent
Nominating and Corporate Governance · Chair
None stated $110,460
Timothy Moran
54 2024
2 years
 Independent
Compensation · Chair
None stated $117,460
Todd Usen
CEO
 59 2024
2 years
 Not independent None stated None stated Paid as CEO
James L. Cox
83 2024
2 years
 Independent
Nominating and Corporate Governance
PAVmed, Inc. $331,336

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

4 disclosed in the proxy filed Apr 30, 2026
Entities affiliated with Perceptive Advisors LLC; Alyeska Master Fund, L.P.; Armistice Capital Master Fund Ltd.; Entities affiliated with Sio Capital Management, LLC; Entities affiliated with ADAR1 Capital Management LLC
described as our related parties
Amount not stated
2025

Purchased shares, pre-funded warrants and Milestone Warrants in the 2025 PIPE Financing.

With the Company Open in proxy
ARYA Sciences Holdings IV (the Sponsor), Class B Shareholders and Insiders, including ARYA's directors and officers
Sponsor, Class B shareholders and Insiders, including ARYA's directors and officers
1,147,500 shares

Sponsor Letter Agreement: Insiders agreed to terminate prior lock-up provisions, and the Sponsor agreed 1,147,500 shares would be subject to vesting based on share price.

With Adagio and Legacy Adagio Open in proxy
Perceptive Life Sciences Master Fund, Ltd. (Perceptive PIPE Investor)
$7,000,000
2024

Conversion of a $7.0 million 2024 Bridge Financing Note into a Convertible Note and Convert Warrants.

With ListCo and Legacy Adagio Open in proxy
Perceptive Life Sciences Master Fund, Ltd. (Perceptive PIPE Investor)
Approximately $15,875,568
2024

Additional cash investment in the 2024 PIPE Financing, along with contribution of convertible promissory notes.

With the Company (Legacy Adagio and ListCo) Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans